Does Blue Shield of California Cover Forteo?

How Blue Shield of California Classifies Forteo on Its Formulary

Blue Shield of California places Forteo (teriparatide) on its specialty medication tier across most plan designs, including HMO, PPO, EPO, and Medicare Advantage products. This means the drug is covered but carries higher cost-sharing than preferred generics or brand-name medications on lower tiers.

Specialty tier placement reflects the drug's wholesale acquisition cost. Forteo's list price sits near $4,100 for a 28-day pen supply, according to pricing data from the FDA's Orange Book and manufacturer labeling. Blue Shield, like most large California insurers, negotiates rebates that reduce the net price, but the member-facing tier assignment still reflects the high gross cost.

Formulary documents published by Blue Shield of California list teriparatide under the endocrine/metabolic category. The plan's drug search tool at blueshieldca.com/formulary confirms placement and any associated utilization management requirements. Plans sold through Covered California (the state ACA exchange) follow the same specialty tier assignment, though cost-sharing structures differ from employer-sponsored coverage.

One detail worth checking: Blue Shield of California operates distinct formularies for its commercial products and its Blue Shield of California Promise Health Plan (Medi-Cal managed care). Medi-Cal managed care formularies follow the California Department of Health Care Services contract drug list. Forteo appears on that list but may require a Treatment Authorization Request (TAR) rather than a standard prior authorization [1].

Prior Authorization Requirements for Forteo

Every Blue Shield of California plan requires prior authorization before dispensing Forteo. The prescribing physician must submit clinical documentation showing the member meets specific medical criteria. This is standard across commercial insurers for anabolic bone agents.

Blue Shield's published prior authorization criteria for teriparatide typically require documentation of the following: a confirmed diagnosis of osteoporosis by DXA scan showing a T-score of -2.5 or lower at the spine, femoral neck, or total hip; history of a fragility fracture (vertebral or non-vertebral); or bone mineral density consistent with osteopenia (T-score between -1.0 and -2.5) plus a high fracture risk score using the FRAX calculator. The Endocrine Society's 2020 clinical practice guideline recommends anabolic therapy as first-line for patients at very high fracture risk, defined as a recent vertebral fracture, T-score below -3.0, or a FRAX 10-year major osteoporotic fracture probability exceeding 30% [2].

Step therapy compounds the authorization process. Blue Shield generally requires that members have tried, failed, or have a documented contraindication to at least one bisphosphonate (alendronate or risedronate) before approving Forteo. "Failed" can mean a new fracture while on therapy, continued bone density decline after 12+ months, or intolerance such as esophageal ulceration. The prescriber must document this in the prior authorization submission.

Processing time runs 5 to 15 business days for standard requests. Urgent requests tied to acute fracture or rapid bone loss can be expedited within 24 to 72 hours under California Department of Managed Health Care timely access rules.

What Forteo Costs Under Blue Shield of California Plans

Your actual out-of-pocket cost depends on your plan's benefit design, deductible status, and whether you've met your annual out-of-pocket maximum. Rough cost brackets look like this.

For commercial PPO/HMO plans with a specialty copay: members typically pay a fixed copay ranging from $75 to $250 per 28-day pen. Some plans use coinsurance instead, charging 20% to 33% of the allowed amount. On a plan with 25% coinsurance and a $3,200 allowed amount, the member share would be $800 per fill before any copay accumulator or manufacturer coupon is applied.

For high-deductible health plans (HDHPs): the member pays the full contracted rate until the deductible is met, which can exceed $3,000 per fill in the pre-deductible phase. After the deductible, coinsurance typically applies.

For Medicare Advantage plans: Forteo falls under Part D (or Part B if administered in a clinical setting, though self-injected Forteo is a Part D drug). Blue Shield's Medicare Advantage Part D plans assign Forteo to a specialty tier with a 25% to 33% coinsurance rate. The Medicare Part D catastrophic coverage phase, which in 2026 kicks in after $2 to 000 in true out-of-pocket spending under the Inflation Reduction Act's $2,000 annual cap, provides significant relief [3]. Once a Medicare Advantage member hits that $2,000 threshold, cost-sharing for Forteo drops to $0 for the remainder of the plan year.

Eli Lilly's Forteo Savings Card can reduce copays to as low as $4 per month for commercially insured patients. This card does not apply to Medicare, Medicaid, or other government-funded plans. Blue Shield of California does not block manufacturer coupons from being used at the pharmacy counter, but plans with copay accumulator programs may prevent coupon dollars from counting toward the member's deductible or out-of-pocket maximum.

Step Therapy: Which Drugs Must Be Tried First

Blue Shield of California's step therapy protocol for Forteo mirrors the approach used by most large insurers and aligns with the American Association of Clinical Endocrinology (AACE) and the Endocrine Society's treatment algorithm [2].

The first-line agents the plan expects prescribers to document include oral bisphosphonates, specifically alendronate (Fosamax, generic) at 70 mg weekly or risedronate (Actonel, generic) at 35 mg weekly or 150 mg monthly. Some plans also accept IV zoledronic acid (Reclast) at 5 mg annually or denosumab (Prolia) at 60 mg subcutaneously every 6 months as the pre-step agent.

There's a clinical tension here. The Endocrine Society guideline published in the Journal of Clinical Endocrinology & Metabolism states: "For patients at very high fracture risk, including those with recent vertebral fracture, we suggest initial treatment with an osteoanabolic agent rather than an antiresorptive" [2]. This means a prescriber can argue for skipping step therapy when a patient qualifies under the "very high risk" definition.

To override step therapy, the prescriber files a step therapy exception request. Blue Shield must respond within 72 hours for standard requests and 24 hours for urgent/expedited requests, per California Health & Safety Code Section 1367.243 [4]. The prescriber should include the patient's FRAX score, DXA results, fracture history, and a citation to the Endocrine Society guideline supporting anabolic-first therapy.

In the VERO trial (N=1,360), teriparatide reduced new vertebral fractures by 56% compared to risedronate over 24 months in postmenopausal women with severe osteoporosis (HR 0.44 to 95% CI 0.29 to 0.68, P<0.001) [5]. This head-to-head data against a bisphosphonate strengthens any exception request arguing that the patient's fracture risk profile warrants anabolic-first therapy.

How Forteo Is Dispensed Through Blue Shield's Specialty Pharmacy

Blue Shield of California contracts with specific specialty pharmacies for high-cost injectable medications. Forteo is classified as a self-administered injectable, which means it flows through the pharmacy benefit rather than the medical benefit.

Most Blue Shield commercial plans route specialty medications through their contracted specialty pharmacy vendor. This is typically a large national specialty pharmacy. Members cannot fill Forteo at a retail pharmacy like CVS or Walgreens. The specialty pharmacy ships the medication to the member's home or physician's office.

The specialty pharmacy handles cold-chain management (Forteo must be refrigerated between 2°C and 8°C), prior authorization coordination with the prescriber, refill reminders, and adherence check-ins. Blue Shield's care management team may also reach out to members starting Forteo to provide injection training resources and monitor for adverse effects.

Refills are dispensed on a 28-day cycle. The pen device delivers 20 mcg of teriparatide per daily subcutaneous injection, yielding 28 doses per pen. The FDA-approved treatment duration is a cumulative maximum of 24 months, which is based on the original safety data showing that rats developed osteosarcoma at high doses over near-lifetime exposure. The FDA's Forteo prescribing information retained the 24-month use limitation, though the 2020 label update removed the boxed warning about osteosarcoma following a 15-year post-marketing surveillance study that showed no increased osteosarcoma signal in humans [6].

What to Do If Blue Shield Denies Forteo Coverage

A denial is not the end. Blue Shield of California members have multiple appeal options, and California state law provides stronger consumer protections than many other states.

The first step after denial is to request a coverage determination review. The prescriber can submit additional clinical documentation, including updated DXA results, fracture history, imaging, and relevant guideline citations. If the plan denies the coverage determination, the member can file a formal grievance.

California's Department of Managed Health Care (DMHC) operates an Independent Medical Review (IMR) process. Any Blue Shield HMO or POS member can request an IMR after exhausting one level of internal appeal. For urgently needed medications, the member can request an expedited IMR simultaneously with the internal appeal. The DMHC reports that approximately 60% of prescription drug IMR decisions result in overturning the health plan's denial [7].

For Blue Shield PPO members subject to Department of Insurance (CDI) jurisdiction rather than DMHC, a similar external review process exists through the CDI.

Dr. Paul Miller, a clinical researcher at the Colorado Center for Bone Research, has noted: "Step therapy requirements for anabolic bone agents can delay appropriate treatment in high-risk patients. When a patient has already fractured, every month of delay represents additional fracture risk that could have been mitigated" [8]. This perspective supports aggressive use of the appeals process for patients meeting very-high-risk criteria.

A practical tip: request a peer-to-peer review. The prescribing physician can speak directly with the Blue Shield medical director reviewing the case. Peer-to-peer conversations resolve many denials without requiring a formal appeal, because the reviewing physician can hear clinical context that documentation alone may not convey.

Forteo vs. Alternatives That May Have Better Coverage

If Forteo's cost-sharing proves prohibitive, Blue Shield of California covers several alternative osteoporosis agents at lower tier positions.

Generic alendronate sits on Tier 1 (preferred generic) with copays typically under $10. Risedronate occupies Tier 1 or Tier 2 depending on the plan. Denosumab (Prolia) is on a specialty tier but may have different step therapy requirements. Abaloparatide (Tymlos), another anabolic agent, is also specialty tier and generally requires the same prior authorization criteria as Forteo.

Romosozumab (Evenity), a sclerostin inhibitor, occupies specialty tier status and carries additional cardiovascular risk screening requirements. The ARCH trial (N=4,093) demonstrated that romosozumab followed by alendronate reduced vertebral fracture risk by 48% compared to alendronate alone over 24 months, but the trial also showed a higher rate of cardiovascular events in the romosozumab group (2.5% vs 1.9%) [9]. Blue Shield requires documentation of cardiovascular risk assessment before approving Evenity.

For patients weighing Forteo vs. Tymlos, the cost-sharing under Blue Shield plans is often comparable since both sit on the same specialty tier. The clinical difference: abaloparatide (Tymlos) produced a 43% relative risk reduction in radiographic vertebral fractures vs. placebo in the ACTIVE trial (N=2,463) over 18 months, with a somewhat lower incidence of hypercalcemia than teriparatide [10]. Some prescribers prefer Tymlos for patients with a history of calcium metabolism issues.

Covered California and Blue Shield Forteo Coverage

Members who purchase Blue Shield plans through Covered California (the state's ACA marketplace) face the same formulary as direct-purchase Blue Shield members, but the plan benefit design follows Covered California's standardized benefit templates.

Covered California's 2026 plan designs cap specialty drug copays at defined levels depending on the metal tier. Bronze plans carry higher specialty copays and deductibles. Silver 94 and Silver 87 plans (enhanced Silver plans for lower-income members) offer substantially reduced cost-sharing, with specialty copays as low as $50 to $100 per fill.

Members earning up to 250% of the federal poverty level qualify for cost-sharing reductions that can make Forteo significantly more affordable. A member on a Silver 94 plan with a $75 specialty copay would pay $75 per month for Forteo, compared to $400+ on a Bronze plan with a 30% coinsurance rate.

Prior authorization and step therapy requirements apply identically regardless of whether the plan was purchased through Covered California or directly from Blue Shield. The clinical criteria do not change based on the purchasing channel.

Medi-Cal Managed Care Coverage Through Blue Shield Promise

Blue Shield of California Promise Health Plan administers Medi-Cal managed care in Los Angeles County and parts of other service areas. Medi-Cal covers Forteo, but the process differs from commercial coverage.

Medi-Cal uses a Treatment Authorization Request (TAR) instead of a standard prior authorization. The TAR process is administered by the state Department of Health Care Services, though Blue Shield Promise handles the review for its managed care enrollees.

Medi-Cal has no member cost-sharing for prescription drugs. Forteo is dispensed at $0 out-of-pocket for Medi-Cal beneficiaries. The primary barrier is the TAR approval process, which can take 5 to 14 business days and requires the same clinical documentation: DXA results, fracture history, and documented bisphosphonate failure or contraindication.

Medi-Cal does not impose formal step therapy in the same way commercial plans do, but the TAR reviewer will evaluate whether less costly alternatives were considered. Providing documentation of clinical rationale for anabolic therapy over bisphosphonates strengthens the request.

Transitioning Off Forteo: What Blue Shield Covers Next

Because Forteo is limited to 24 months of cumulative therapy, patients need a transition plan. Bone density gains from teriparatide are lost rapidly if no antiresorptive agent follows. The DATA-Switch extension study showed that transitioning from teriparatide to denosumab continued to increase BMD at the spine and hip, while discontinuing all therapy led to measurable bone loss within 12 months [11].

Blue Shield of California covers denosumab (Prolia), zoledronic acid (Reclast), and oral bisphosphonates as follow-on agents after Forteo. A new prior authorization is required for Prolia or Reclast, but the fact that the patient was previously approved for Forteo typically satisfies the clinical criteria for an antiresorptive, since the underlying osteoporosis diagnosis and fracture risk are already documented.

The Endocrine Society recommends: "Following completion of a course of teriparatide or abaloparatide, we recommend treatment with an antiresorptive agent (bisphosphonate or denosumab) to maintain BMD gains" [2]. This guideline language directly supports the transition authorization request.